MedPath

The use of antibiotics in therapy resistant Lichen Sclerosus patientes

Phase 1
Conditions
Vulvar Lichen Sclerosus
Registration Number
EUCTR2009-011906-40-NL
Lead Sponsor
Radboud University Nijmegen Medical Centre
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Female
Target Recruitment
10
Inclusion Criteria

Vulvar Lichen Sclerosus patients who do not or hardly respons to the standard therapy (ultrapotent corticosteroids)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

History of differentiated vulvar intraepithelial neoplasia or vulvar squamous cell carcinoma

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: Relief of symptoms;Secondary Objective: Improvement of clinical picture<br>Improvement of histological abnormalities<br>Effect on quality of life<br>Demonstration of Borrelia species in the biopsies via culture and PCR<br>Demonstration of antibodies to Borrelia species in serum of patients<br>Feasibility for the patient;Primary end point(s): Relief of symptoms
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath